KALA

Company Overview — What Does KALA BIO, Inc. Do?

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts. KALA BIO, Inc. (KALA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Mark T. Iwicki and employs approximately 30 people. With a market capitalization of $149M, KALA is one of the notable companies in the Healthcare sector.

KALA BIO, Inc. (KALA) Stock Rating — Avoid (April 2026)

As of April 2026, KALA BIO, Inc. receives a Avoid rating with a composite score of 18.5/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.KALA ranks #4,393 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, KALA BIO, Inc. ranks #820 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

KALA Stock Price and 52-Week Range

KALA BIO, Inc. (KALA) currently trades at $0.21. The stock gained $0.03 (14.7%) in the most recent trading session. The 52-week high for KALA is $20.60, which means the stock is currently trading -99.0% from its annual peak. The 52-week low is $0.23, putting the stock -9.9% above its annual trough. Recent trading volume was 3.3M shares, reflecting moderate market activity.

Is KALA Overvalued or Undervalued? — Valuation Analysis

KALA BIO, Inc. (KALA) carries a value factor score of 29/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth.

At current multiples, KALA BIO, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

KALA BIO, Inc. Profitability — ROE, Margins, and Quality Score

KALA BIO, Inc. (KALA) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 3969.1%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at -146.3% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

KALA Debt, Balance Sheet, and Financial Health

KALA BIO, Inc. has a debt-to-equity ratio of -328.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.75x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $27M. Cash and equivalents stand at $21M.

KALA has a beta of 1.43, meaning it is more volatile than the broader market — a $10,000 investment in KALA would be expected to move 43.4% more than the S&P 500 on any given day. The stability factor score for KALA BIO, Inc. is 12/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

KALA BIO, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, KALA BIO, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.07. Net income for the quarter was $-37M. Operating income came in at $-39M.

In Q3 2025, KALA BIO, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.07. Net income for the quarter was $-8M. Operating income came in at $-7M.

In Q2 2025, KALA BIO, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.71. Net income for the quarter was $-11M. Operating income came in at $-11M.

In Q1 2025, KALA BIO, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.41. Net income for the quarter was $-9M. Operating income came in at $-11M.

Over the past 8 quarters, KALA BIO, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing KALA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

KALA Dividend Yield and Income Analysis

KALA BIO, Inc. (KALA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

KALA Momentum and Technical Analysis Profile

KALA BIO, Inc. (KALA) has a momentum factor score of 7/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 49/100 reflects moderate short selling activity.

KALA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, KALA BIO, Inc. (KALA) ranks #820 out of 838 stocks based on the Blank Capital composite score. This places KALA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing KALA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full KALA vs S&P 500 (SPY) comparison to assess how KALA BIO, Inc. stacks up against the broader market across all factor dimensions.

KALA Next Earnings Date

No upcoming earnings date has been announced for KALA BIO, Inc. (KALA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy KALA? — Investment Thesis Summary

The quantitative profile for KALA BIO, Inc. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 29/100 indicates premium valuation. Momentum is weak at 7/100, a headwind for near-term performance. High volatility (stability score 12/100) increases portfolio risk.

In summary, KALA BIO, Inc. (KALA) earns a Avoid rating with a composite score of 18.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on KALA stock.

Related Resources for KALA Investors

Explore more research and tools: KALA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare KALA head-to-head with peers: KALA vs AZN, KALA vs SLGL, KALA vs VMD.